Silo Pharma 過去の業績

過去基準チェック /06

Silo Pharmaの収益は年間平均-15.6%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間19.3% 28%割合で増加しています。

主要情報

-15.6%

収益成長率

14.6%

EPS成長率

Biotechs 業界の成長	17.0%
収益成長率	28.0%
株主資本利益率	-57.8%
ネット・マージン	-4,778.2%
前回の決算情報	30 Jun 2024

Recent updates

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Oct 20

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Oct 03

収支内訳

Silo Pharma の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqCM:SILO 収益、費用、利益 ( )USD Millions
日付	収益	G+A経費	研究開発費
30 Jun 24	-3	3	1
31 Mar 24	-4	3	1
31 Dec 23	-4	3	1
30 Sep 23	-4	3	1
30 Jun 23	-5	3	1
31 Mar 23	-4	3	1
31 Dec 22	-4	2	1
30 Sep 22	-3	2	1
30 Jun 22	4	2	1
31 Mar 22	4	2	1
31 Dec 21	3	2	1
30 Sep 21	3	2	0
30 Jun 21	-4	2	0
31 Mar 21	-5	3	0
31 Dec 20	-3	2	0
30 Sep 20	-3	2	0
30 Jun 20	-2	2	0
31 Mar 20	-1	1	0
31 Dec 19	-1	1	0
30 Sep 19	-1	1	0
30 Jun 19	-1	1	0
31 Mar 19	-1	1	0
31 Dec 18	-1	0	0
30 Sep 18	0	0	0
30 Jun 18	-1	0	0
31 Mar 18	0	0	0
31 Dec 17	0	0	0
30 Sep 17	0	0	0
30 Jun 17	0	0	0
31 Mar 17	0	0	0
31 Dec 16	-1	0	0
30 Sep 16	-1	0	0
30 Jun 16	-1	0	0
31 Mar 16	-1	0	0
31 Dec 15	0	0	0
30 Sep 15	0	0	0
30 Jun 15	0	0	0
31 Mar 15	-1	0	0
31 Dec 14	0	0	0
30 Sep 14	0	0	0
30 Jun 14	0	0	0
31 Mar 14	0	0	0
31 Dec 13	0	0	0

質の高い収益: SILOは現在利益が出ていません。

利益率の向上: SILOは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: SILOは利益が出ておらず、過去 5 年間で損失は年間15.6%の割合で増加しています。

成長の加速: SILOの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: SILOは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( 16.6% ) と比較することは困難です。

株主資本利益率

高いROE: SILOは現在利益が出ていないため、自己資本利益率 ( -57.83% ) はマイナスです。

Silo Pharma 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.32 loss in 2Q 2023)

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.29 loss in 1Q 2023)

Full year 2023 earnings: EPS misses analyst expectations

Third quarter 2023 earnings: EPS exceeds analyst expectations

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.33 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.31 loss in 1Q 2022)

Recent updates

Silo Pharma, Inc. Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant

Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024

Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024

Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.32 loss in 2Q 2023)

Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.100005 million.

Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.100005 million.

Silo Pharma, Inc. announced that it has received $2.077409 million in funding

New minor risk - Shareholder dilution

Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.000002 million.

Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.000002 million.

New major risk - Share price stability

Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety

Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention

First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.29 loss in 1Q 2023)

Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment

Full year 2023 earnings: EPS misses analyst expectations

Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery

Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology

Silo Pharma Announces Positive Results in Alzheimer’s Disease Study

Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD

New minor risk - Share price stability

Third quarter 2023 earnings: EPS exceeds analyst expectations

Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023

Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis

Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA

Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD

Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.33 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.31 loss in 1Q 2022)

Silo Pharma, Inc. Announces Spc-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’S Disease

Full year 2022 earnings released: US$1.71 loss per share (vs US$1.45 profit in FY 2021)

Silo Pharma Announces Filing of Patent for Treatment of Alzheimer's

Silo Pharma, Inc. (NasdaqCM:SILO) announces an Equity Buyback for $1 million worth of its shares.

Silo Pharma, Inc. Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation

Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis

Silo Pharma, Inc. Initiates Study of Novel Joint Homing Peptide in Human Tissue

High number of new and inexperienced directors

Third quarter 2022 earnings released: US$0.49 loss per share (vs US$3.28 profit in 3Q 2021)

Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation

Investor sentiment deteriorated over the past week

High number of new and inexperienced directors

Silo Pharma, Inc. Announces Data Supporting Therapeutic Potential of SPC -14 for Alzheimer's Disease in Pre-Clinical Study

Silo Pharma spikes on pre-clinical data for Alzheimer's candidate

Investor sentiment improved over the past week

High number of new and inexperienced directors

Silo Pharma Initiates Toxicity Study of Proprietary Ketamine Formulation for Treatment of Fibromyalgia

Silo Pharma, Inc. Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology

Silo Pharma begins pre-IND process for topical ketamine formulation for fibromyalgia

Silo Pharma, Inc. Announces Positive Results from its Topically Administered Formulation of Ketamine

Silo Pharma, Inc. Announces Positive Results in Subcutaneous Delivery of Its Novel Liposomes to Treat Arthritic Patients

Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study

Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study

Silo Pharma, Inc. Enters into Exclusive Option Agreement with the University of Maryland, Baltimore for Patented Homing Peptides Targeting Rheumatoid Arthritis

Silo Pharma, Inc. Enters into A Master License Agreement with the University of Maryland, Baltimore

Silo Pharma Inc. announced that it expects to receive $4.276 million in funding

Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease

Silo Pharma Inc. Announces Licensing Agreement with Aikido Pharma Inc

Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities

Silo Pharma, Inc. Appoints Charles B. Nemeroff to Scientific Advisory Board

Silo Pharma Inc. Appoints Peter Hendricks to its Scientific Advisory Board

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’S Disease

Silo Pharma, Inc. Names Joshua Woolley to Newly Formed Scientific Advisory Board

Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Matthew Johnson of John Hopkins University

Silo Pharma, Inc. Enters into Option Agreement with University of Maryland Baltimore for Central Nervous System-Homing Peptides

Silo Pharma, Inc. Appoints Kevin Muñoz to Board of Directors

収支内訳

収益と収入の歴史

フリー・キャッシュフローと収益の比較

過去基準チェック /06